TOP HEADLINES

Featured Story

  • Pfizer's U.S. Prevnar 13 sales jump 87% in Q2

    The world's biggest vaccine by sales--Prevnar 13--just keeps getting bigger. And in doing so, the shot helped Pfizer notch 44% vaccines growth for the second quarter as the unit saw sales grow from $1.09 billion in last year's Q2 to $1.58 billion during the period this year.

Sanofi's dengue vax protects two-thirds of people aged 9 and up: NEJM

As it works to introduce its dengue vaccine in endemic countries around the world, Sanofi Pasteur this week touted efficacy results from two Phase III studies in a move to help build the case for wide uptake.

Bavarian Nordic starts PhII of Prostvac in early-stage cancer

Looking to expand its potential market for prostate cancer immunotherapy candidate Prostvac, Bavarian Nordic has announced that it's beginning a Phase II trial for its vaccine in early-stage prostate cancer, representing another possible avenue to broaden the candidate's reach.

GSK envisions 'thoughtful, staged rollout' for Mosquirix

GlaxoSmithKline's malaria jab got the green light from the EMA on Friday and the British pharma is making plans for a gradual rollout of the vaccine.

NIH's MERS vaccine looks promising in mice

Investigators at the NIH have developed a new MERS vaccine that looks promising in mice. Focusing on the structure of a viral protein that the MERS virus uses to enter cells, the researchers developed a two-step, prime-boost process.

SutroVax bags $22M Series A to develop vaccines for infectious diseases

SutroVax, the vaccine spinoff from Fierce 15 honoree Sutro Biopharma that is developing vaccines for infectious diseases, announced Thursday the completion of a $22 million Series A financing.

MORE NEWS

From Our Sister Sites

FierceAnimalHealth

Veterinary diagnostics maker IDEXX reported on Thursday that its revenues for the second quarter grew 6% year over year to $413 million, as placements of its blood analysis systems hit a record of 900 units for the period. Placements of its Catalyst One next-generation chemistry analyzer skyrocketed 44% to an all-time record of 1,100 units, the company said in a press release announcing the results.

FierceAnimalHealth

Distributor Henry Schein, which is undergoing a major expansion of its animal health business, reported that earnings in the second quarter grew 8% year over year to $123.2 million or $1.46 per diluted share, on sales that rose a half-percent to $2.6 billion.